profit from every $100 of sales.
$0$100
Forian
We have no price for Forian since 15 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$2.17+0.00% today
-6.1% since Oct 10, 25
1-year low $2.031-year high $2.49
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Forian sold, what it kept, and what it did with the cash.
Sales went from $16.4 million in 2022 to $30.3 million in 2025, with -$2.87 million of profit last year.
SalesProfit
Forian handed back 14% of the cash it generated last year.
Buybacks $412,944
Free cash flow 2025$3M
Bought back its own shares$412,944
Paid as dividends–
Cash vs. debt$13M vs. $12,137
Forian vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Forian | No profit yet | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Forian's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 16 | 21 | 20 | 30 | |
| 11 | 16 | 13 | 16 | |
| -14 | -3 | -6 | -2 | |
| -18 | 3 | -3 | -2 | |
| -26 | 12 | -4 | -3 | |
| -0.81 | 0.34 | -0.12 | -0.09 | |
| 69.2% | 74.2% | 63.6% | 53.2% | |
| -82.4% | -15.6% | -27.6% | -8.2% | |
| -158.2% | 55.5% | -18.7% | -9.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 46 | 60 | 47 | 44 |
| Cash | 3 | 6 | 5 | 13 |
| Total debt | 25 | 25 | 7 | 0 |
| Total liabilities | 34 | 33 | 17 | 14 |
| 12 | 28 | 30 | 30 | |
| 32 | 32 | 31 | 31 | |
| -38.5% | 5.0% | -6.4% | -6.6% | |
| -209.1% | 42.5% | -12.5% | -9.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | 1 | 0 | 3 | |
| 0 | 0 | – | – | |
| -9 | 1 | 0 | 3 | |
| Dividends paid | – | – | – | – |
| 0 | 3 | 0 | 0 | |
| 12 | 7 | 7 | 3 |
Valuation
- –
- –
- –
- –
- 2.2×
- 23.5×
- –
- 4.3%
- -4.2%
- –
Profitability
- 53.2%
- -8.2%
- -9.5%
- –
- –
- –
- –
- –
- –
- –
Growth
- +22.6%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 872
Top 25%of 867
Top 25%of 986
What analysts expect
- Average price target
- $4.50
- Range
- $4.50 – $4.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.09 | 0.02 | −550.0% |
| Mar 27, 2026 | -0.04 | 0.01 | −500.0% |
| Nov 14, 2025 | 0.02 | 0.01 | +100.0% |
| Aug 13, 2025 | 0.03 | 0.01 | +200.0% |
| May 14, 2025 | -0.04 | 0.02 | −300.0% |
| Mar 31, 2025 | -0.01 | 0.02 | −150.0% |
| Nov 13, 2024 | 0.03 | 0.02 | +66.7% |
| Aug 14, 2024 | -0.03 | -0.01 | −300.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
47No pass
Philip Fisher
36No pass
Peter Lynch
27No pass
Joel Greenblatt
0No pass
Charlie Munger
26No pass
Terry Smith
28No pass
Questions about Forian
Is Forian a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Forian AI analysis
What does Forian do?
Forian Inc. delivers advanced software solutions, proprietary data insights, and sophisticated predictive analytics. It is in Medical - Healthcare Information Services.
Does Forian pay a dividend?
No. Forian does not pay a dividend at the moment; in 2025 it returned $412,944 to shareholders by buying back its own shares.
Who are Forian's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Forian's.
Prices: daily closes to May 15, 2026. Fundamentals: company reports via invest-like data.